EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 18 / No 3 (August 2011) Parasite, 18 3 (2011) 207-214 References
Open Access
Review
Issue
Parasite
Volume 18, Number 3, August 2011
Page(s) 207 - 214
DOI https://doi.org/10.1051/parasite/2011183207
Published online 15 August 2011
  1. Anstey N.M., Russell B., Yeo T.W. & Price R.N. The pathophysiology of vivax malaria. Trends Parasitol, 2009, 25, 220–227. [CrossRef] [PubMed] [Google Scholar]
  2. Atteke C., Ndong J.M., Aubouy A., Maciejewski L., Brocard J., Lebibi J. & Deloron P. In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J Antimicrob Chemother, 2003, 51, 1021–1024. [CrossRef] [PubMed] [Google Scholar]
  3. Baird J.K. Effectiveness of antimalarial drugs. N Engl J Med, 2005, 352, 1565–1577. [CrossRef] [PubMed] [Google Scholar]
  4. Baird J.K. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev, 2009, 22, 508–534. [CrossRef] [PubMed] [Google Scholar]
  5. Barends M., Jaidee A., Khaohirun N., Singhasivanon P. & Nosten F. In vitro activity of ferroquine (SSR97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malaria J, 2007, 6, 81. [CrossRef] [Google Scholar]
  6. Beagley P., Blackie M.A.L., Chibale K., Clarkson C., Moss J.R. & Smith P.J. Synthesis and antimalarial activity in vitro of new ruthenocene-chloroquine analogues. Dalton Trans, 2002, 2002, 4426–4433. [CrossRef] [Google Scholar]
  7. Beagley P., Blackie M.A.L., Chibale K., Clarkson C., Meijboom R., Moss J.R., Smith P.J. & Su H. Synthesis and antiplasmodial activity in vitro of new ferrocene-chloroquine analogues. Dalton Trans, 2003, 2003, 3046–3051. [CrossRef] [Google Scholar]
  8. Biot C., Glorian G., Maciejewski L.A., Brocard J.S., Millet P., Georges A.J., Abessolo H., Dive D. & Lebibi J. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J Med Chem, 1997, 40, 3715–3718. [CrossRef] [PubMed] [Google Scholar]
  9. Biot C., Delhaës L., N’DIAYE C.M., Maciejewski L.A., Camus D., Dive D. & Brocard J.S. Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds. Bioorg Med Chem, 1999, 7, 2843–2847. [CrossRef] [PubMed] [Google Scholar]
  10. Biot C., Taramelli D., Forfar-Bares I., Maciejewski L.A., Boyce M., Nowogrocki G., Brocard J.S., Basilico N., Olliaro P., Egan T.J. Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm, 2005, 2, 185–193. [CrossRef] [PubMed] [Google Scholar]
  11. Biot C., Daher W., Jarry C., Ndiaye C.H., Pelinski L., Khalife J., Fraisse L., Brocard J., Melnyk P., Forfar-Bares I. & Dive D. Probing the role of the covalent linkage of ferrocene into a chloroquine template. J Med Chem, 2006a, 49, 4707–4714. [CrossRef] [Google Scholar]
  12. Biot C., Daher W., Chavain N., Fandeur T., Khalife J., Dive D. & de Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem, 2006b, 49, 2845–2849. [CrossRef] [Google Scholar]
  13. Biot C, Pradines B., Sergeant M.H., Gut J., Rosenthal P.J. & Chibale K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg Med Chem Lett, 2007, 17, 6434–6438. [CrossRef] [PubMed] [Google Scholar]
  14. Biot C, Chavain N., Dubar F., Pradines B., Brocard J., Forfar I. & Dive D Structure-activity relationships of 4-N-substituted ferroquine analogues. Time to re-evaluate the mechanism of action of ferroquine. J Organomet Chem, 2009, 694, 845–854. [CrossRef] [Google Scholar]
  15. Biot C. & Dive D. Bioorganometallic chemistry and malaria. Top Organomet Chem, 2010, 32, 155–193. [CrossRef] [Google Scholar]
  16. Blackie M.A., Beagley P., Croft S.L., Kendrick H., Moss J.R. & Chibale K. Metallocene-based antimalarials: an exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Bioorg Med Chem, 2007, 15, 6510–6516. [CrossRef] [PubMed] [Google Scholar]
  17. Blackie M.A. & Chibale K. Metallocene antimalarials: the continuing quest. Met Based Drugs, 2008, 2008, 495123. [PubMed] [Google Scholar]
  18. Chavain N., Vezin H., Dive D., Touati N., Paul J.F., Buisine E. & Biot C. Investigation of the redox behavior of ferroquine, a new antimalarial. Mol Pharm, 2008, 5, 710–716. [CrossRef] [PubMed] [Google Scholar]
  19. Chavain N., Davioud-Charvet E., Trivelli X., Mbeki L., Rottmann M., Brun R. & Biot C. Antimalarial activities of ferroquine conjugates with either glutathione reductase inhibitors or glutathione depletors via a hydrolyzable amide linker. Bioorg Med Chem, 2009, 17, 8048–8059. [CrossRef] [PubMed] [Google Scholar]
  20. Chavain N. & Biot C. Organometallic complexes: new tools for chemotherapy. Curr Med Chem, 2010, 17, 2729–2745. [CrossRef] [PubMed] [Google Scholar]
  21. Chim P., Lim P., Sem R., Nhem S., Maciejewski L. & Fandeur T. The in-vitro antimalarial activity of ferrochloroquine, measured against Cambodian isolates of Plasmodium falciparum. Ann Trop Med Parasitol, 2004, 98, 419–424. [CrossRef] [PubMed] [Google Scholar]
  22. Daher W.E., Pelinski L., Klieber S., Sadoun F., Meunier V., Bourrie M., Biot C., Guillou F., Fabre G., Brocard J., Fraisse L., Maffrand J.P., Khalife J. & Dive D. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos, 2006a, 34, 667–682. [CrossRef] [Google Scholar]
  23. Daher W., Biot C., Fandeur T., Jouin H., Pelinski L., Viscogliosi E., Fraisse L., Pradines B., Brocard J., Khalife J. & Dive D. Assessment of P. falciparum resistance to ferroquine in field isolates and in W2 strain under pressure. Malaria J, 2006b, 5, 11. [CrossRef] [Google Scholar]
  24. Delhaës L., Biot C., Berry L., Maciejewski L.A., Camus D., Brocard J.S. & Dive D. Novel ferrocenic artemisinin derivatives: synthesis, in vitro antimalarial activity and affinity of binding with ferroprotoporphyrin IX. Bioorg Med Chem, 2000, 8, 2739–2745. [CrossRef] [PubMed] [Google Scholar]
  25. Delhaës L., Abessolo H., Biot C., Deloron P., Karbwang J., Mortuaire M., Maciejewski L.A., Camus D., Brocard J. & Dive D. Ferrochloroquine, a ferrocenyl analogue of chloroquine, retains a potent activity against resistant Plasmodium falciparum in vitro and P. vinckei in vivo. Parasitol Res, 2001, 87, 239–244. [CrossRef] [PubMed] [Google Scholar]
  26. Delhaës L., Biot C., Berry L., Delcourt P., Maciejewski L.A., Camus D., Brocard J.S. & Dive D. Synthesis of ferroquine enantiomers. First investigation of metallocenic, chirality upon antimalarial activity and cytotoxicity. ChemBioChem, 2002, 3, 101–106. [CrossRef] [PubMed] [Google Scholar]
  27. Desjardin R.E., Canfield C., Haynes J. & Chulay J. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother, 1979, 16, 710–718. [Google Scholar]
  28. Dhanawat M., Das N., Nagarwal R.C. & Shrivastava S.K. Antimalarial drug development: past to present scenario. Mini Rev Med Chem, 2009, 9, 1447–1469. [CrossRef] [PubMed] [Google Scholar]
  29. Dive D. & Biot C. Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial. ChemMedChem, 2008, 3, 383–391. [CrossRef] [PubMed] [Google Scholar]
  30. Dondorp A.M., Yeung S., White L., Nguon C., Day N.P., Socheat D. & von Seidlein L. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol, 2010, 8, 272–280. [CrossRef] [PubMed] [Google Scholar]
  31. Dubar F., Egan T.J., Pradines B., Kuter D., Ncokazi K.K., Forge D., Paul J.P., Pierrot C., Kalamou H., Khalife J., Buisine E., Rogier C., Vezin H., Forfar I., Slomianny C., Trivelli X., Kapishnikov S., Leiserowitz L., Dive D. & Biot C. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem Biol, 2011, 6 (3), 275–287. [CrossRef] [PubMed] [Google Scholar]
  32. Dunitz J., Orgel L. & Rich A. The crystal structure of ferrocene. Acta Cryst, 1956, 9, 373–375. [CrossRef] [Google Scholar]
  33. Henry M., Briolant S., Fontaine A., Mosnier J., Baret E., Amalvict R., Fusaï T., Fraisse L., Rogier C. & Pradines B. In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother, 2008, 52, 2755–2759. [CrossRef] [PubMed] [Google Scholar]
  34. Kreidenweiss A., Kremsner PG., Dietz K. & Mordmueller B. In vitro activity of ferroquine (SSR97193) is independent of chloroquine resistance in Plasmodium falciparum. Amer J Trop Med Hyg, 2006, 75, 1178–1181. [Google Scholar]
  35. Leimanis M.L., Jaidee A., Sriprawat K., Kaewpongsri S., Suwanarusk R., Barends M., Phyo A.P., Russell B., Renia L. & Nosten F. Plasmodium vivax susceptibility to ferroquine. Antimicrob Agents Chemother, 2010, 54, 2228–2230. [CrossRef] [PubMed] [Google Scholar]
  36. Nosten F. & White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg, 2007, 77, 181–192. [PubMed] [Google Scholar]
  37. Olliaro P. & Wells TN. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther, 2009, 85, 584–595. [CrossRef] [PubMed] [Google Scholar]
  38. Peters W. , in: Chemotherapy, and drug resistance in malaria. Peters W. (ed.). Liverpool: LiverpoolSchool of Tropical Medicine, 1987, Vol. 1, 145–273. [Google Scholar]
  39. Pradines B., Fusaï T., Daries W., Laloge V., Rogier C., Millet P., Panconi E., Kombila M. & Parzy D. Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J Antimicrob Chemother, 2001, 48, 179–184. [CrossRef] [PubMed] [Google Scholar]
  40. Pradines B., Tall A., Rogier C., Spiegel A., Mosnier J., Marrama L., Fusï T., Millet P., Panconi E., Trape J.F. & Parzy D. In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop Med Int Health, 2002, 7, 265–270. [CrossRef] [PubMed] [Google Scholar]
  41. Stratton L., O’Neill MS., Kruk M.E. & Bell M.L. The persistent problem of malaria: addressing the fundamental causes of a global killer. Social Sci Med, 2008, 67, 854–862. [Google Scholar]
  42. Vessieres A., Jaouen G., Gruselle M., Rossignol JL., Savignac M., Top S. & Greenfield S. Synthesis and receptor binding of polynuclear organometallic estradiol derivatives. J Steroid Biochem, 1988, 30, 301–316. [CrossRef] [PubMed] [Google Scholar]
  43. White NJ. Antimalarial drug resistance and combination therapy. Philos Trans R Soc London B Biol Sci, 1999, 354, 739–749. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.